Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing next-generation targeted therapies for endocrine-driven cancers. The company's primary focus is on estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Its lead clinical candidate, palazestrant (OP-1250), is an orally available small molecule designed to function as both a complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD). In addition to palazestrant, Olema is advancing OP-3136, an oral KAT6 inhibitor targeting epigenetic mechanisms dysregulated in breast and other cancers. The company operates primarily out of San Francisco and currently generates no commercial product revenue, relying instead on capital markets and partnerships to advance its clinical pipeline.
